High cholesterol is one of those things most people discover too late. It rarely makes noise until it shows up in a test report or after a heart scare. In India, where heart disease claims more lives than any other condition, managing cholesterol is often a long, exhausting battle — daily pills, lifestyle shifts, and endless check-ups.
But now, something radically different is stirring global curiosity.
An experimental drug from Verve Therapeutics is promising to lower harmful LDL cholesterol by 69% — with just one injection. It uses precision gene-editing to switch off a tiny gene called PCSK9, the one responsible for keeping bad cholesterol stubbornly high in some people. Think of it as turning off a tap that never needed to be open in the first place.
Experimental drug promising to bring down bad cholesterol by up to 69% completes early stage trial
In early trials, patients who received this shot saw dramatic drops in their LDL levels — with no serious side effects so far. Larger trials are underway in five countries, and if results hold up, this could redefine how we treat high cholesterol, moving from lifelong pills to a single, decisive intervention.
For India, where cardiovascular disease hits younger and harder, the implications are serious. Not because it’s the next fancy Western drug, but because it offers a chance to stop heart problems before they start — especially for those who won’t catch it in time or stick to years of medication.
A single jab to silence bad cholesterol? If it delivers, it’s not just medicine. It’s a message.